RxDoctor Payments Data

Richard Rucker, MD

Internal Medicine · Los Alamitos, CANPI 1659477685

Payments from drug & device makers

$2,674in general payments, 2019–2025

Across 115 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$578
  • Pfizer$329
  • GSK$293
  • Philips North America LLC$211
  • Merck$200
  • Lilly USA, LLC$167
  • plus $896 from 19 others

What the payments were for

  • Food & beverage$2,64699%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,674 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$379,999
Medicare patients
643
Services billed
3,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$73,925
EliquisApixaban53$58,294
OzempicSemaglutide31$53,054
JardianceEmpagliflozin13$22,311
XareltoRivaroxaban15$21,539
JanuviaSitagliptin Phosphate13$11,784
Wixela InhubFluticasone Propion/Salmeterol13$4,702
Omega-3 Acid Ethyl Esters19$3,317
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen77$3,063
PaxlovidNirmatrelvir/Ritonavir12$2,858
Fenofibrate43$2,263
Albuterol Sulfate HfaAlbuterol Sulfate74$2,260
Gabapentin73$1,765
Atorvastatin Calcium194$1,676
Potassium Chloride50$1,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$293$73,92561 claims
PfizerEliquis, Paxlovid$329$61,15265 claims
Boehringer IngelheimJardiance$25$22,31113 claims
Johnson & JohnsonXarelto$578$21,53915 claims
MerckJanuvia$200$11,78413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Alamitos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →